Find AP-002 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: R3g3hb38o4, Gallium, tris(8-quinolinolato)-, Tris(8-hydroxyquinolinato)gallium, Nkp-2235, Ap-002, It-235
Molecular Formula
C27H18GaN3O3
Molecular Weight
502.2  g/mol
InChI Key
KWQNQSDKCINQQP-UHFFFAOYSA-K
FDA UNII
R3G3HB38O4

AP-002
Gallium-based Bone Resorption Inhibitor AP-002 is an orally bioavailable gallium (Ga)-based small molecule agent with potential anti-bone resorption and antineoplastic activities. Upon oral administration, AP-002 selectively inhibits osteoclast differentiation and bone resorption, and may promote the growth of osteoblasts thereby improving the skeletal sequelae of bony metastases which include pain, spinal cord compression, fractures and hypercalcemia of malignancy. Additionally, AP-002 may, through an as of yet undescribed mechanism of action, directly target and kill bone tumor cells.
1 2D Structure

AP-002

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
gallium;quinolin-8-olate
2.1.2 InChI
InChI=1S/3C9H7NO.Ga/c3*11-8-5-1-3-7-4-2-6-10-9(7)8;/h3*1-6,11H;/q;;;+3/p-3
2.1.3 InChI Key
KWQNQSDKCINQQP-UHFFFAOYSA-K
2.1.4 Canonical SMILES
C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.[Ga+3]
2.2 Other Identifiers
2.2.1 UNII
R3G3HB38O4
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. R3g3hb38o4

2. Gallium, Tris(8-quinolinolato)-

3. Tris(8-hydroxyquinolinato)gallium

4. Nkp-2235

5. Ap-002

6. It-235

7. Lx-001

8. Gallium;quinolin-8-olate

9. Unii-r3g3hb38o4

10. Kp46

11. Nsc 158197

12. Nsc-158197

13. Gallium, Tris(8-quinolinolato-kappan1,kappao8)-

14. Gallium, Tris(8-quinolinolato-.kappa.n1,.kappa.o8)-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 502.2 g/mol
Molecular Formula C27H18GaN3O3
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count0
Exact Mass501.06039 g/mol
Monoisotopic Mass501.06039 g/mol
Topological Polar Surface Area108 Ų
Heavy Atom Count34
Formal Charge0
Complexity138
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count4

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty